Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01369602 · ClinicalTrials.gov registry record · Phase 1
Study To Evaluate The Effect Of Renal Impairment On The Pharmacokinetics Of PF-04991532
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
NCT01369602 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 27 participants.
The verdict
NCT01369602, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
Study Summary
The primary purpose of this study is to evaluate the pharmacokinetics, safety and tolerability of a single oral dose of PF-04991532 in subjects with renal impairment.
Interventions
- DRUG PF-04991532
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2011-07 |
| Est. Completion | 2012-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01369602
The ClinicalTrials.gov registry entry for NCT01369602 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PF-04991532 is the first listed.
NCT01369602 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01369602 about?
NCT01369602 is a clinical study titled "Study To Evaluate The Effect Of Renal Impairment On The Pharmacokinetics Of PF-04991532". The primary purpose of this study is to evaluate the pharmacokinetics, safety and tolerability of a single oral dose of PF-04991532 in subjects with renal impairment.
What is the current status of trial NCT01369602?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2011-07. Estimated completion is 2012-02.
What interventions are being tested in trial NCT01369602?
The interventions under investigation include: PF-04991532 (DRUG).
Who is sponsoring clinical trial NCT01369602?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.